Cardiology
Latest news
974 articles · 20 / page
Comprehensive Review of Digital Nudges to Enhance Influenza Vaccination Uptake in Chronic and Cardiovascular Disease Patients
Electronic behavioral nudges significantly improve influenza vaccination rates among patients with chronic and cardiovascular diseases, offering scalable public health strategies.
Repurposing Hydroxychloroquine for Chronic Inflammatory Cardiomyopathy: Evidence from the HYPIC Multicenter Randomized Trial
The HYPIC trial demonstrates that hydroxychloroquine combined with prednisolone significantly improves cardiovascular outcomes, cardiac function, and cytokine profiles in patients with chronic inflammatory cardiomyopathy following fulminant
A Universal Threshold? High-Sensitivity Troponin I Emerges as a Robust Prognostic Tool in Wild-Type Transthyretin Amyloid Cardiomyopathy
A multicenter study identifies 80 ng/L as a critical hs-cTnI threshold for mortality risk in wild-type transthyretin amyloid cardiomyopathy, offering a standardized approach for staging and prognosis across various diagnostic assays.
Redefining Iron Deficiency in Heart Failure: Why TSAT and Serum Iron Outperform Ferritin for Prognosis
Recent large-scale studies, including HEART-FID and major national registries, demonstrate that transferrin saturation (TSAT) and serum iron levels are more accurate predictors of functional capacity and mortality in heart failure than trad
Beyond Sodium Restriction: Legumes and Vegetables Linked to Improved Outcomes in Heart Failure
A substudy of the global G-CHF registry demonstrates that higher intake of legumes and vegetables significantly reduces the risk of death and hospitalization in heart failure patients, while refined grains increase risk, highlighting the im
Empagliflozin Enhances Cardiovascular Protection in HFrEF Patients with Low Serum Magnesium: Evidence from EMPEROR-Reduced
This analysis of the EMPEROR-Reduced trial demonstrates that empagliflozin increases serum magnesium levels and provides a more pronounced reduction in cardiovascular events for patients with low baseline magnesium, revealing a novel electr
PDE9 Inhibition with CRD-740 Safely Elevates cGMP Levels in HFrEF: Results from the CARDINAL-HF Trial
The Phase 2 CARDINAL-HF trial demonstrates that CRD-740, a novel PDE9 inhibitor, significantly increases plasma and urinary cGMP in patients with heart failure and reduced ejection fraction. The treatment was well tolerated and effective ev
Elevated Natriuretic Peptides: A Potent Predictor of Heart Failure and Mortality in Asymptomatic Diabetes
A large-scale cohort study demonstrates that screening natriuretic peptide levels in individuals with type 1 or type 2 diabetes significantly predicts incident heart failure and death, advocating for routine biomarker-based risk stratificat
Beyond the Scale: Abdominal Adiposity Outperforms BMI in Predicting Outcomes for HFpEF and HFmrEF
A pooled analysis of 21,479 HFpEF/HFmrEF patients reveals that waist-to-height ratio is a superior, linear predictor of mortality and heart failure events compared to BMI. Even in non-obese BMI categories, nearly 90% of patients exhibit exc
Rethinking Biomarker Thresholds: Why Current NT-proBNP Cutoffs Fail Patients with Obesity and HFpEF
A pooled analysis of 14,750 patients reveals that current fixed NT-proBNP thresholds significantly underestimate cardiovascular risk in obese patients with heart failure, suggesting a critical need for BMI-adjusted diagnostic and trial elig
Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP
A post-hoc analysis of the Look AHEAD trial demonstrates that NT-proBNP levels can identify patients with type 2 diabetes who benefit most from intensive lifestyle interventions. ILI significantly reduced HFpEF risk in those with elevated o
Cardiac Progenitor Cells in Hypoplastic Left Heart Syndrome: Safety Established, but Efficacy Remains Elusive in the CHILD Trial
The Phase I CHILD trial demonstrates that intramyocardial injection of neonatal cardiac progenitor cells during HLHS palliation is safe but does not improve right ventricular function at one year, despite promising signals in secondary clin
Finerenone in the Management of HFmrEF and HFpEF: A Comprehensive Synthesis of Evidence from the FINEARTS-HF Trial
This clinical review synthesizes data from the FINEARTS-HF trial, highlighting finerenone’s efficacy in reducing heart failure events and cardiovascular mortality across diverse patient profiles, including those with frailty, obesity, and c
Finerenone and Hypotension Risk in Heart Failure: Evidence from the FINEARTS-HF Trial
This analysis of the FINEARTS-HF trial identifies that while finerenone increases hypotension risk in HFmrEF and HFpEF patients, its clinical benefits persist. The study highlights key predictors of hypotension, such as low baseline blood p
Nanosecond Pulsed Field Ablation Matches Radiofrequency Efficacy While Slashing Procedure Time: Insights From the InsightPFA Trial
The InsightPFA trial confirms that a novel nanosecond pulsed field ablation (nsPFA) system is noninferior to radiofrequency ablation for paroxysmal atrial fibrillation, significantly reducing procedure and left atrial dwell times while main
Beyond Beta-Blockers: Aficamten Reinvents First-Line Therapy for Obstructive Hypertrophic Cardiomyopathy
The MAPLE-HCM trial demonstrates that aficamten monotherapy provides superior, rapid, and comprehensive clinical benefits compared to the traditional first-line treatment, metoprolol, across multiple disease domains in patients with symptom
Comparative Efficacy, Safety, and Complications of Subcutaneous Versus Transvenous Implantable Cardioverter-Defibrillators: Insights from the PRAETORIAN and ATLAS Trials and Meta-Analyses
This review synthesizes randomized trial data comparing subcutaneous and transvenous ICDs, highlighting differences in inappropriate shocks, device-related complications, and shock efficacy, underscoring clinical considerations for ICD sele
High BMI, High Benefit: How PCSK9 Inhibition Optimizes Outcomes in Obese Patients with ASCVD
A prespecified analysis of the FOURIER trial reveals that patients with obesity and atherosclerotic cardiovascular disease experience significantly higher absolute and relative risk reductions with evolocumab, particularly those with a BMI
Statin Initiation and Follow-Up Testing Are Declining in Young Adults Despite High Cardiovascular Risk
A large-scale study of over 700,000 young adults reveals a concerning decline in lipid follow-up and statin initiation between 2008 and 2018, highlighting a critical care gap in preventing premature cardiovascular disease during a key windo
Myval THV Demonstrates 1-Year Noninferiority to Established Transcatheter Heart Valves: Insights from the LANDMARK Trial
The LANDMARK trial reports that the novel Myval balloon-expandable transcatheter heart valve is clinically noninferior to contemporary SAPIEN and Evolut series at one year, offering comparable safety, hemodynamic performance, and quality-of
Browse by specialty
Open language-specific specialty feeds and department pages.